BPC-157 works through different mechanisms (NO modulation, growth factor signaling) than these drugs, making pharmacological overlap unlikely
Andrea Corona Altimmunes GLP-1 drug shows positive results for alcohol use disorder On Tuesday, Altimmune announced topline data from their Phase 2 RECLAIM trial showing that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced the number of heavy drinking days compared to placebo in patients with moderate to severe alcohol use disorder
After first use, refrigerate and discard after 28 days
A shot of reality WHICH BRINGS US back to Juan Leija, the personal trainer who turned to BPC-157 to deal with his worsening elbow pain
Access is limited by regulation, so a personalized, physician-supervised protocol with ongoing lab monitoring is essential for safe, realistic results